What does specialty surgery — operating income (loss) mean?

This metric measures the profitability of the Specialty Surgery segment by subtracting total operating costs from segment revenues. It is the primary indicator of the segment's operational efficiency and its ability to contribute to the company's overall bottom-line performance.

Integra LifeSciences (IART) Specialty Surgery — Operating Income (Loss)

Screener

Other segment segments

Tissue Reconstruction

$18.94M—

Similar metrics at other companies

AMRXSpecialty — Operating Income (Loss)

$54.86M+54.6%

CRSSpecialty Alloys Operations — Operating Income (Loss)

$229.7M+34.6%

GTL

GTLSSpecialty Products — Operating Income (Loss)

$8.4M-82.6%

APGSpecialty Services — Operating Income (Loss)

$39M+34.5%

BCPCSpecialty Products — Operating Income (Loss)

$11.94M+24.5%

DORMSpecialty Vehicle — Operating Income (Loss)

$4.09M-15.2%

Other financials

Income statement

See full

Revenue$418.8M+0.8%

Gross profit$219.7M+5.0%

Operating income$19.3M+104%

Net income$4.5M+101%

EPS (diluted)$0.06+101%

Balance sheet

See full

Cash & equivalents$214.4M-1.6%

Total debt$2.0B+3.2%

Total equity$1.0B+0.5%

Total assets$3.6B-2.8%

Cash flow

See full

Operating cash flow$22.8M+156%

CapEx$12.3M-38.9%

Free cash flow$10.5M+193%

Valuation

See full

Market cap$1.33B+38.0%

Enterprise value$3.08B+16.2%

P/S0.8×+0.2×

Profitability

See full

Gross margin52.5%-0.1pp

Operating margin2.6%+1.3pp

Net margin-0.4%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-0.7%—

Debt / equity1.9×+0.1×

Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed: Jul 29, 2026, 4:03 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0000917520-26-000058

Dollars in thousands	Three Months Ended June 30, 2026 / Specialty Surgery	Three Months Ended June 30, 2026 / Tissue Reconstruction	Three Months Ended June 30, 2026 / Corporate and Other	Three Months Ended June 30, 2026 / Total	Six Months Ended June 30, 2026 / Specialty Surgery	Six Months Ended June 30, 2026 / Tissue Reconstruction	Six Months Ended June 30, 2026 / Corporate and Other	Six Months Ended June 30, 2026 / Total
Selling, general & administrative	75,983	40,394	56,059	172,436	153,664	83,920	113,087	350,671
Intangible asset amortization	—	—	3,770	3,770	—	—	7,546	7,546
Total cost and expenses	220,395	90,552	88,529	399,476	420,404	179,069	180,451	779,924
Operating income (loss)	88,874	18,940	(88,529)	19,285	172,000	39,206	(180,451)	30,755
Interest income				4,267				8,372
Interest expense				(22,994)				(45,459)
Other income, net				4,186				8,665
Income before income taxes				$4,744				$2,333

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's specialty surgery — operating income (loss)?: Integra LifeSciences (IART) reported specialty surgery — operating income (loss) of $88.87M in Q2 2026.
What does specialty surgery — operating income (loss) mean?: This metric measures the profitability of the Specialty Surgery segment by subtracting total operating costs from segment revenues. It is the primary indicator of the segment's operational efficiency and its ability to contribute to the company's overall bottom-line performance.